# Molecular Epidemiology and evolutionary characteristics of dengue virus serotype-2 strains in Sri Lanka

Dinuka Ariyaratne[1,2], Tibutius Thanesh, Pramanayagam Jayadas[1], Chandima Jeewandara[1,2], Malithi De Silva[1], Bhagya Senadheera[1], Laksiri Gomes[1], Farha Bary[1], Ayesa Syenina[3,4], Diyanath Ranasinghe[1], Heshan Kuruppu[1], Ananda Wijewickrama[2], Eng Eong Ooi[3,4], Gathsaurie Neelika Malavige[1,2*]

[1]Institute of Allergology and Immunology, University of Sri Jayewardenepura, Sri Lanka

[2]Department of Immunology and Molecular Medicine, Faculty of Medical Sciences, University of Sri Jayewardenepura, Sri Lanka

[3]National Institute of Infectious Diseases, Angoda, Sri Lanka

[4]Programme in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore

[5]Viral Research and Experimental Medicine Centre, SingHealth Duke-NUS Academic Medical Centre, Singapore

**Correspondence should be addressed to:**

Prof. Neelika Malavige DPhil (Oxon), FRCP (Lond), FRCPath

AICBU, Department of Immunology and Molecular Medicine, Faculty of Medical Sciences, University of Sri Jayewardenepura, Sri Lanka

Tel +94 (0) 772443193

## Abstract

**Background:** Surveillance and characterization of different dengue virus (DENV) lineages of different serotypes causing outbreaks is crucial for initiation of timely dengue control measures and for implementing dengue vaccines. Therefore, we characterized the DENV-2 strains in Sri Lanka from 2016, until end of 2023 and their evolutionary dynamics to understand the geographical spread and mutations arising with the DENV-2 serotypes in Sri Lanka

**Methodology:** Sequencing was carried out on 80 DENV-2 samples collected from patients with acute dengue recruited from 2016 to 2018 and 12 DENV-2 samples from 2022 to 2023 using Oxford Nanopore Technology. Phylogenetic analysis was carried out using the IQ-TREE tool within Galaxy to construct a phylogenetic tree from the aligned sequence data. The sequences were also analyzed for non-synonymous amino acid changes in the envelope and NS1 regions.

**Results:** The Sri Lankan DENV-2 sequences circulating from 2016 to end of 2023 were found to belong to genotype II.F.1 lineage. They were closely related to strains circulating during the same period in South Asia and Southeast Asia. We identified 15 non-synonymous mutations within the envelope region and 22 non-synonymous mutations within the NS1 region, with 7 non-synonymous mutations within the E region (M6I, Q52H, E71A, V129I, N390S, I484V, T478S) and 10 non-synonymous mutations within the NS1 region (S80T, T117A, Q131H, K174R, F178S, N222S, L247F, I264T, T265A, K272R) seen in all sequenced samples. Some of these mutations were previously shown to be associated with increase in viral replication, NS1 secretion and immune evasion.

**Conclusions:** Given the increase in dengue transmission in many countries, it is important to further strengthen DENV surveillance for studying the evolutionary patterns of the DENV to initiate timely and appropriate control measures.

**Keywords:** dengue; virus; serotypes; genotypes; mutations; transmission; evolution; pathogenicity; virulence; sequence

## Background

There has been an alarming rise of dengue infections in all regions of the world, with year 2024 reporting the highest number of dengue cases so far[1]. Over 13 million cases were reported globally by August 2024, though the actual number is likely to be higher due to under reporting and the difficultly in clinically differentiating dengue from many other similar febrile infections[1, 2]. Yet, the number of dengue infections is forecasted to keep rising every year while spreading to new geographical regions due to multiple factors such as climate change, rapid urbanization, population displacements and possibly rapid evolution of the dengue virus (DENV)[3]. As a result, the World Health Organization has included it in the R&D Blueprint as an emerging pathogen of pandemic potential[4].

Dengue infections are caused by four related but genetically distinct dengue virus serotypes (DENV1 to 4), which share 75% to 80% homology with each other. Each DENV serotype consists of multiple lineages with a nucleotide diversity of 6 to 8%[5, 6]. Although DENVs are endemic in many countries in the tropical and subtropical regions, major shifts in the circulating DENV serotype leads to large outbreaks, overwhelming health care systems[7-10]. Moreover, due to increased transmission rates, many countries have reported co-circulation of multiple DENV serotypes and lineages resulting in outbreaks[11-13]. Different DENV lineages have been shown to result in different magnitudes of infectivity, viral titers and pathogenicity in *in vitro* models[14], with certain lineages known to cause more severe infection and larger outbreaks[15, 16]. These phenotypic differences between the DENV lineages may be attributed to sequence-dependent virus-host interactions. For instance, a

single nucleotide substitution in an American DENV2 genotype may explain the lack of outbreak in Tonga in contrast to large number of severe dengue cases elsewhere in the Pacific during the early 1970s[17] DENV has a similar evolution rate to SARS-CoV-2 ($10^{-3}$ nucleotide substitution per site/year), which increases to $10^{-4}$ nucleotide substitutions per site/year, during outbreaks[18-20]. Moreover, immunity from dengue vaccination and the use of Wolbachia mosquitoes in vector control may impose new selection pressures on DENV, thus creating the possibility of new virus lineages. Therefore, surveillance and characterization of circulating DENV lineages of different serotypes would be important to understand how they may affect clinical disease severity and transmission dynamics. In this study, we characterized the DENV-2 strains in Sri Lanka from 2016, until end of 2023 and their evolutionary dynamics to understand the geographical spread and mutations arising with the DENV-2 serotypes in Sri Lanka.

# Methods

**Recruitment of patients with acute dengue infection for serotyping PCR and DENV sequencing**

Blood samples were collected from 582 adult patients who were clinically suspected to have an acute dengue infection, following informed consent during the period of July 2016 to October 2018, and again 467 adult patients were recruited between November 2022 to December 2023, in the National Institute of Infectious Diseases (NIID), Angoda, Sri Lanka. Quantitative real time PCR for detection of the four DENVs were carried out in all samples to determine the infecting DENV serotype using modified CDC primers as previously described[21].

**Ethical Approval**

Ethics approval for the study was obtained from the Ethics Review Committee, University of Sri Jayewardenepura and the administrative clearance was obtained from the Ministry of Health, Sri Lanka. All individuals gave informed written consent.

**Whole genomic sequencing of the DENV2 that circulated in Sri Lanka during 2017 to 2018 and 2023**

As DENV-2 was the predominant circulating serotype since mid-2016 and was responsible for over 95% of infections in 2017[15], 80/582 DENV2 positive samples from mid-2016 to end of 2018 and 12/467 DENV2 positive samples from November 2022 to December 2023 were selected for sequencing using an amplicon-based framework [22] All samples selected for sequencing passed the cycle threshold value of <25. Briefly, cDNA was synthesized from viral RNA using the SuperScript IV First-Strand Synthesis System (Life Technologies) – for the 80 samples collected from 2016-2018, or Lunascript (LunaScriptTM RT SuperMix Kit,

New England Biolabs, E3010) – for the 12 samples collected between 2022-2023. Amplicons were then generated using Q5 Hot Start High-Fidelity DNA Polymerase (New England Biolabs) with DENV-2 specific primers. The PCR mixture was initially incubated for 30s at 98 ◦C for denaturation, followed by 35 cycles of 98 ◦C for 15 s and 65 ◦C for 5 min. The PCR products were then diluted 10-fold. Subsequently, the diluted amplicons were end-prepped and dA-tailed using NEBNext Ultra II End Repair/dA-Tailing Module. Native barcodes and sequencing adapters supplied in the EXP-NBD101/114 kit (Oxford Nanopore Technologies) were attached to the dA-tailed amplicons using NEB Blunt/TA Ligase 2x Master Mix and NEBNext Quick Ligation Kit, respectively. Finally, 15 ng of DNA library was loaded on to the R9.4.1 flow cell following the SQK-LSK109 ligation sequencing kit (Oxford Nanopore Technologies) protocol, the sequencing run was performed on the Minion Mk1b (Oxford Nanopore Technologies) for a total of 24 hours. Reads were basecalled using the MinKnow software.

**Bioinformatics analysis**

The sequences were analyzed and compared with other DENV-2 sequences from Sri Lanka collected in 1996 (GenBank FJ882602.1) and 2003 (GenBank GQ252677.1), accessed from GISAID. The initial alignment of the FASTA files was done with MAFFT and the phylogenetics tree was built using IQTree. The sequences were then analyzed for non-synonymous amino acid changes in the envelope and NS1 regions. Out of these non-synonymous changes, we selected the amino acid mutations unique to the 2016/2017/2018 and 2022/2023 sequences compared to the reference genome (GenBank NC001474.2)

**Generation of Maximum-Likelihood Tree**

After generating FASTA files for all sequences sequenced in 2017 to 2023, sequences with more than 70% coverage overall and 100% coverage of E and NS1 regions were selected (n=63). They were aligned with the reference sequence NC 001474.2 and previous Sri Lankan DENV-2 sequences from 1996 (GenBank FJ882602) and 2003 (GenBank GQ252676) using MAFFT [23]by running on the public server of the web platform Galaxy (http://usegalaxy.org).

These aligned sequences were run in Nextclade [24] website (https://clades.nextstrain.org) to classify the genomes based on the latest classification [6](https://dengue-lineages.org/ )and to analyze the non-synonymous mutations and resulting amino acid changes in the E andNS1 regions. Publicly available DENV-2 sequences (n=362) were downloaded from NCBI Virus [25]database. The sequences were filtered to obtain complete whole genome sequences from Asia and South America between 01.01.1994-28.10.2024. These sequences (n=425) were aligned with the previous sequences and redundant sequences were removed. The aligned sequences were then used to build a maximum-likelihood tree (1000 bootstraps) using IQ-Tree[26]. The tree was then visualized in the online tree viewing platform Interactive Tree of Life [27] (https://itol.embl.de/), colour coded and annotated.

**Molecular Clock Analysis**

We undertook a comprehensive approach for molecular clock analysis of DENV-2, starting with sequence collection and preparation. Initially, we gathered a total of 63 DENV-2 sequences from Sri Lanka, which were organized in FASTA format. To supplement this dataset, we retrieved additional DENV-2 sequences from the National Center for Biotechnology Information (NCBI) database, specifically focusing on sequences from human hosts with a minimum length of 10,000 nucleotides. We excluded sequences from

environmental sources and laboratory-passaged sequences, resulting in the collection of 754 sequences.

Next, we standardized the FASTA headers across both the Sri Lankan and NCBI datasets using a Python script to ensure consistency, adopting the format: >Reference_Description_Date. These sequences were then uploaded to the Galaxy platform using its "Upload Data" tool for data processing, where we merged them into a single FASTA file with the "Concatenate FASTA" tool, culminating in a combined dataset of 817 sequences. Subsequently, we performed multiple sequence alignment using MAFFT in Galaxy, and any sequence lacking a recorded collection year was eliminated from the dataset. To enhance clade annotation, we uploaded the aligned sequences to Nextclade, which provided clade information that was then downloaded in Excel format. We created a comprehensive metadata CSV file containing sequence names, collection dates, and clade information, ensuring that any sequence missing date or clade information was excluded.

For phylogenetic analysis, we employed the IQ-TREE tool within Galaxy to construct a phylogenetic tree from the aligned sequence data, subsequently downloading the tree in Newick format. The resulting phylogenetic tree file, along with the metadata CSV, was utilized as input for Clockor2[28] to conduct the molecular clock analysis. Clockor2 facilitated root-to-tip regression analysis, allowing us to infer both global and local strict molecular clocks. During this analysis, it was observed that NCBI sequences belonging to clade 2I exhibited a downward regression trend, prompting their removal to ensure accurate molecular clock estimation. The decision to exclude these sequences was based on their deviation from expected evolutionary rates, which could potentially introduce bias into the molecular clock inference.

**Geospatial Mapping of Dengue Serotype 2 lineages**

For visualizing the geographical distribution of DENV-2 lineages, we leveraged a geospatial visualization approach utilizing Python's geospatial data libraries. First, we loaded the metadata of DEN-2, which included information on sequence lineages and their locations, from a TSV file into a Pandas DataFrame. This metadata file was downloaded from the Nextstrain platform for comprehensive genomic analysis of DENV-2.

To map these data points, we utilized a Natural Earth shapefile representing world countries at a high resolution (10m scale). This shapefile was loaded as a GeoDataFrame using the Geopandas library, ensuring that the geographical information of each country could be effectively utilized in plotting. Certain location names in the metadata, like 'California (USA)' and 'Florida (USA)', were standardized to 'United States of America' to ensure accurate mapping. We then merged the metadata DataFrame with the GeoDataFrame of world countries based on location names, aligning DENV-2 lineage data with their respective geographical geometries.

The resulting GeoDataFrame was filtered to retain only valid geometries, and centroid calculation was performed for plotting purposes. We utilized Matplotlib to initialize a plot, setting the world map boundaries with a light grey color. The DENV-2 lineage points were overlaid on this map, color-coded according to lineage, using the HSV colormap for differentiation.

**Statistical Analysis**

R (version 4.4.1) using R packages stats, dplyr, ggplot2, ggpubr, tidyverse,ggsignify, patchwork, pheatmap. K-means clustering was conducted using R with the stats package. We chose k = [3] based on the elbow method. The kmeans function was then applied with nstart = 20 to minimize the risk of local optima. All the R and Python code used for analysis and figure generation can be accessed at: https://github.com/AICBU/DENV2_SriLanka.

## Results

### Full-length genomic sequence of the circulating DENV-2 in Sri Lanka

The largest dengue outbreak in Sri Lanka was happened in 2017 due to the emergence of DENV-2 resulting in 186,101 hospital admissions [15]. Whole genome sequencing of DENV2 positive samples collected during the outbreak between 2017-2018 found the circulating DENV2 strain to be genotype II, major lineage F and minor lineage 1 (genotype II.F.I) based on the latest classification of DENVs (Figure 1)[6]. Phylogenetically, the 2017/18 sequences were closely related to strains circulating during the same period in China and other Asian countries such as Thailand, Singapore and Malaysia (Figure 1). DENV2 positive samples were also collected between 2022-2023. Whole genome sequencing on these samples revealed they were of the same genotype II F1.1 strain as the 2017/2018 samples. The 2017/2018 and 2022/2023 sequences formed a new DENV-2 genotype II.F.I clade, clustering with other previously reported 2017 Sri Lankan DENV-2 strains (MT180479, GenBank)[29], and genetically distant from the previous DENV-2 strains that circulated in Sri Lanka from 1996 to 2003, which belonged to DENV-2 genotype II_A (Sup Figure 1). These DENV-2 strains from 1990s and early 2000s belong to the major lineage A, which was mainly reported from Africa in the 1990s, which has since evolved to II_A1 by 2007 and subsequently II_A2.2 by 2018 (Figure 2). The more recent F1.1 lineage is predominantly spread in East and Southeast Asia (Figure 2).

### Evolution of DENV-2 genotype II. F.I strains in Sri Lanka

The Sri Lankan DENV-2 strains that were responsible for the large outbreak in 2017, gradually evolved from 2016 to 2023, with the sequences falling along regression line as shown in the molecular clock analysis (Figure 3). The Sri Lankan DENV-2 genotype II. F.I

strains thus appeared to evolve at a similar rate (1.445 x $10^{-3}$) compared to evolutionary rates of other reported DENV2 strains globally (1.45× 10−3) (Supplementary Table 1)[30].

**Characterization of mutations specific to E and NS1 in DENV-2 genotype II.F.I**

Analysis of the mutations within DENV-2 genotype II.F.I compared to the reference genome (GenBank: NC 001474.2) showed 15 non-synonymous mutations within the envelope (E) region and 22 non-synonymous mutations within the NS1 region, occurring with varying frequencies (Supplementary Table 2). There were 7 non-synonymous mutations within the E region (M6I, Q52H, E71A, V129I, N390S, I484V, T478S) and 10 non-synonymous mutations within the NS1 region (S80T, T117A, Q131H, K174R, F178S, N222S, L247F, I264T, T265A, K272R) seen in all 48 samples. These non-synonymous mutations within the E protein were seen in the fusion loop (one), EDI (two), EDII (one), EDIII (one) and transmembrane region (two). All sequenced DENV-2 genotype II.F.I strains shared a "core" set of E□protein and NS1□protein changes (Figure 4). Some of the newer substitutions, such as the W453C in E proteins or the F279L mutation in the NS1 protein are not seen in the DENV-2 genotype II.F.I strains in 2017/2018 but only appear in the strains sequenced during the 2022 to 2023 period (Figure 4). However, due to the relatively small sample size of a total of 63 sequences used in this study, how these different sub-lineages arising out of the DENV-2 genotype II.F.I associated with clinical disease outcomes could not be analysed.

## Discussion

In this study we have sequenced DENV-2 strains which emerged in mid-2016, that were responsible for the largest dengue outbreak in Sri Lanka in 2017. Although these DENV-2, genotype II strains were classified as belonging to the cosmopolitan genotype[15], based on the earlier DENV genotype classification, using the new proposed classification, they were found to form a new lineage of genotype II.F.I[6]. Although the cosmopolitan genotype of DENV-2 was reported from all regions in the world[16], DENV-2 genotype II.F.1 was only reported in South Asia and Southeast Asia. This shows how the new DENV classification provides more granularity regarding the evolution and geographical spread of the DENV genotypes as it enables characterization of sub-lineages of different genotypes. With the introduction of different dengue vaccines, understanding dengue epidemiology at more granular genomic level could be increasingly important. For instance, the CYD-TDV phase III vaccine trial showed different DENV2-specific vaccine efficacy in Asian and Latin American populations.[31, 32] These differences may, at least in part, have been influenced by the antigenic distance between the vaccine strain and circulating DENV reduced CYD-TDV vaccine efficacy across study sites[33, 34]. Therefore, given that the strains used to develop the currently licensed dengue vaccines composed of historical DENV strains, it is important to continuously carry our surveillance of different DENV strains in different parts of the world.

Our DENV-2 genotype II.F.I strains showed a similar evolutionary rate as other DENV-2 strains[30]. We observed 15 non-synonymous mutations within the envelope region and 22 non-synonymous mutations within the NS1 region in this strain. Three mutations within the envelope region (E71A, H149N and N390S) have been previously described as mutations

unique to the DENV-2 cosmopolitan genotype[16]. In addition to these three previously described mutations, the four other new mutations seen in all strains were seen in domains I, II, III and the transmembrane region of the protein. Therefore, it would be important to study further if these mutations could affect the binding of neutralizing antibodies and thereby possibly leading to re-infection with DENV-2 as described previously[35, 36]. All sequenced DENV-2 strains from 2016 to end of 2023, showed 10 non-synonymous mutations within the NS1. Although these mutations have not been previously described as being unique to the cosmopolitan strain, some of these mutations have shown to be associated with pathogenicity. For instance, the T117A was shown to produce 12-fold more intracellular virus than the wild-type strains[37]. The K272R substitution in NS1, which was identified in the DENV-2 virus that led to a large outbreak in 2015 in Taiwan, was shown replicate faster, produce more secretory NS1 in cell culture supernatants and inhibited STAT1 phosphorylation thereby inhibiting interferon signaling pathways[38]. While some other mutations observed by us have been described in other DENV-2 genotypes[14], DENV-2 genotype III in Brazil [39] and in other genotypes[29], it would be important to further study the implications of these mutations in transmission of the virus and altering its pathogenicity.

## Conclusions

In summary, in this study we have characterized the DENV-2 strains from 2016 to end of 2023, which were responsible for the largest ever dengue outbreak in Sri Lanka, which were found to be genotype II.F.I. These DENV-2 strains have been widely reported in South Asia and Southeast Asia and were found to have certain unique mutations which have been associated with increase in viral replication, NS1 secretion and immune evasion. Given the increase in dengue transmission in many countries, it is important to further strengthen

DENV surveillance for studying the evolutionary patterns of the DENV to initiate timely and appropriate control measures.

## Abbreviations

CDC: Centers for Disease Control

DENV: Dengue virus

RNA: Ribonucleic acid

STAT1: Signal transducer and activator of transcription 1

## Declarations

### Ethics approval and consent to participate

Ethics approval was obtained from the Ethics Review Committee of the University of Sri Jayewardenepura. All participants gave informed written consent.

### Consent for publication

Not applicable.

### Availability of data and material

All data is available within the manuscript and the supporting files.

### Competing interests

EEO has served in advisory capacities on dengue for Sanofi Pasteur, Takeda Pharmaceuticals, MSD, Johnson & Johnson and Novartis. GNM has served in advisory capacities on dengue for Johnson & Johnson, Novartis and Abbott.

**Funding**

We are grateful to the NIH, USA (grant number 5U01AI151788-02), Accelerating Higher Education Expansion and Development (AHEAD) Operation of the Ministry of Higher Education funded by the World Bank. Eng Eong Ooi is supported by a career award from the National Medical Research Council of Singapore (MOH-001271-00).

**Authors' contributions**

Conceptualization: DA, GNM, TTPJ

Data curation: DA, HK, LG, TTPJ, AW

Experiments and investigations: DA, TTPJ, HK, LG, FB, AS

Data analysis: BS, MDS, DR

Project administration and supervision: GNM, CJ, EEO, AW

Funding acquisition: GNM, CJ, EEO

Writing the manuscript: DA, GNM, EEO

Reviewing the manuscript: EEO

## References:


1. The L. Dengue: the threat to health now and in the future. Lancet. 2024;404(10450):311; doi: 10.1016/S0140-6736(24)01542-3.

2. Malavige GN, Wijewickrama A, Ogg GS. Differentiating dengue from other febrile illnesses: a dilemma faced by clinicians in dengue endemic countries. Lancet Glob Health. 2023;11(3):e306-e7; doi: 10.1016/S2214-109X(22)00547-2.

3. Malavige GN, Sjo P, Singh K, Piedagnel JM, Mowbray C, Estani S, et al. Facing the escalating burden of dengue: Challenges and perspectives. PLOS Glob Public Health. 2023;3(12):e0002598; doi: 10.1371/journal.pgph.0002598.

4. WHO: Pathogens Prioritization. A scientific framework for epidemic and pandemic research prepradeness. In.; 2024: 60.

5. Weaver SC, Vasilakis N. Molecular evolution of dengue viruses: contributions of phylogenetics to understanding the history and epidemiology of the preeminent arboviral disease. Infect Genet Evol. 2009;9(4):523-40.

6. Hill V, Cleemput S, Pereira JS, Gifford RJ, Fonseca V, Tegally H, et al. A new lineage nomenclature to aid genomic surveillance of dengue virus. PLoS Biol. 2024;22(9):e3002834; doi: 10.1371/journal.pbio.3002834.

7. Malavige GN, Jeewandara C, Ghouse A, Somathilake G, Tissera H. Changing epidemiology of dengue in Sri Lanka-Challenges for the future. PLoS neglected tropical diseases. 2021;15(8):e0009624; doi: 10.1371/journal.pntd.0009624.

8. Sarker R, Roknuzzaman ASM, Emon FA, Dewan SMR, Hossain MJ, Islam MR. A perspective on the worst ever dengue outbreak 2023 in Bangladesh: What makes this

old enemy so deadly, and how can we combat it? Health Sci Rep. 2024;7(5):e2077; doi: 10.1002/hsr2.2077.

9. Guzman MG, Halstead SB, Artsob H, Buchy P, Farrar J, Gubler DJ, et al. Dengue: a continuing global threat. Nature reviews. 2010;8(12 Suppl):S7-16; doi: 10.1038/nrmicro2460.

10. Saha K, Ghosh M, Firdaus R, Biswas A, Seth B, Bhattacharya D, et al. Changing pattern of dengue virus serotypes circulating during 2008-2012 and reappearance of dengue serotype 3 may cause outbreak in Kolkata, India. Journal of medical virology. 2016;88(10):1697-702; doi: 10.1002/jmv.24529.

11. Ariyaratne D, Senadheera B, Kuruppu H, Pramanayagam Jayadas TT, Gomes L, Ranasinghe D, et al. Simultaneous co-circulation of two genotypes of dengue virus serotype 3 causing a large outbreak in Sri Lanka in year 2023. The Journal of infectious diseases. 2024; doi: 10.1093/infdis/jiae474.

12. Amorim MT, Naveca FG, Hernandez LHA, da Paz TYB, da Silva de Oliveira CC, da Conceicao Miranda Santos A, et al. Detection of a Multiple Circulation Event of Dengue Virus 2 Strains in the Northern Region of Brazil. Trop Med Infect Dis. 2024;9(1); doi: 10.3390/tropicalmed9010017.

13. Napit R, Elong Ngono A, Mihindukulasuriya KA, Pradhan A, Khadka B, Shrestha S, et al. Dengue virus surveillance in Nepal yields the first on-site whole genome sequences of isolates from the 2022 outbreak. BMC genomics. 2024;25(1):998; doi: 10.1186/s12864-024-10879-x.

14. Samune Y, Saito A, Sasaki T, Koketsu R, Srimark N, Phadungsombat J, et al. Genetic regions affecting the replication and pathogenicity of dengue virus type 2. PLoS neglected tropical diseases. 2024;18(1):e0011885; doi: 10.1371/journal.pntd.0011885.

15. Tissera HA, Jayamanne BDW, Raut R, Janaki SMD, Tozan Y, Samaraweera PC, et al. Severe Dengue Epidemic, Sri Lanka, 2017. Emerging infectious diseases. 2020;26(4):682-91; doi: 10.3201/eid2604.190435.

16. Yenamandra SP, Koo C, Chiang S, Lim HSJ, Yeo ZY, Ng LC, et al. Evolution, heterogeneity and global dispersal of cosmopolitan genotype of Dengue virus type 2. Sci Rep. 2021;11(1):13496; doi: 10.1038/s41598-021-92783-y.

17. Choi ANX, Siriphanitchakorn T, Choy MM, Ooi JSG, Manuel M, Tan HC, et al. A prM mutation that attenuates dengue virus replication in human cells enhances midgut infection in mosquitoes. Science Translational Medicine. 2024;16(758):eadk4769; doi: doi:10.1126/scitranslmed.adk4769.

18. Abbasian MH, Mahmanzar M, Rahimian K, Mahdavi B, Tokhanbigli S, Moradi B, et al. Global landscape of SARS-CoV-2 mutations and conserved regions. Journal of translational medicine. 2023;21(1):152; doi: 10.1186/s12967-023-03996-w.

19. Fajardo A, Recarey R, de Mora D, L DA, Alvarez M, Regato M, et al. Modeling gene sequence changes over time in type 3 dengue viruses from Ecuador. Virus research. 2009;141(1):105-9; doi: 10.1016/j.virusres.2009.01.003.

20. Ariyaratne D, Senadheera B, Kuruppu H, Jayadas TTP, Gomes L, Ranasinghe D, et al. Simultaneous co-circulation of two genotypes of dengue virus serotype 3 causing a large outbreak in Sri Lanka in year 2023. medRxiv. 2024:2024.05.09.24307112; doi: 10.1101/2024.05.09.24307112.

21. Fernando S, Wijewickrama A, Gomes L, Punchihewa CT, Madusanka SD, Dissanayake H, et al. Patterns and causes of liver involvement in acute dengue infection. BMC infectious diseases. 2016;16:319; doi: 10.1186/s12879-016-1656-2.

22. Quick J, Grubaugh ND, Pullan ST, Claro IM, Smith AD, Gangavarapu K, et al. Multiplex PCR method for MinION and Illumina sequencing of Zika and other virus genomes directly from clinical samples. Nat Protoc. 2017;12(6):1261-76; doi: 10.1038/nprot.2017.066.

23. Katoh K, Standley DM. MAFFT Multiple Sequence Alignment Software Version 7: Improvements in Performance and Usability. Molecular Biology and Evolution. 2013;30(4):772-80; doi: 10.1093/molbev/mst010.

24. Aksamentov I, Roemer C, Hodcroft E, Neher R. Nextclade: clade assignment, mutation calling and quality control for viral genomes. Journal of Open Source Software. 2021;6(67); doi: 10.21105/joss.03773.

25. NCBI Virus. https://www.ncbi.nlm.nih.gov/labs/virus/vssi/#/virus?SeqType_s=Nucleotide&VirusLineage_ss=dengue%20virus%20type%202,%20taxid:11060 accessed Nov 17th, 2024 Accessed November 17th, 2024.

26. Trifinopoulos J, Nguyen LT, von Haeseler A, Minh BQ. W-IQ-TREE: a fast online phylogenetic tool for maximum likelihood analysis. Nucleic Acids Res. 2016;44(W1):W232-5; doi: 10.1093/nar/gkw256.

27. Letunic I, Bork P. Interactive Tree of Life (iTOL) v6: recent updates to the phylogenetic tree display and annotation tool. Nucleic Acids Res. 2024;52(W1):W78-W82; doi: 10.1093/nar/gkae268.

28. Featherstone LA, Rambaut A, Duchene S, Wirth W. Clockor2: Inferring Global and Local Strict Molecular Clocks Using Root-to-Tip Regression. Syst Biol. 2024;73(3):623-8; doi: 10.1093/sysbio/syae003.

29. Sharma A, Krishna S, Sowdhamini R. Bioinformatics Analysis of Mutations Sheds Light on the Evolution of Dengue NS1 Protein With Implications in the Identification of Potential Functional and Druggable Sites. Mol Biol Evol. 2023;40(3); doi: 10.1093/molbev/msad033.

30. Wei K, Li Y. Global evolutionary history and spatio-temporal dynamics of dengue virus type 2. Sci Rep. 2017;7:45505; doi: 10.1038/srep45505.

31. Capeding MR, Tran NH, Hadinegoro SRS, Ismail HIHJM, Chotpitayasunondh T, Chua MN, et al. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. The Lancet. 2014;384(9951):1358-65; doi: https://doi.org/10.1016/S0140-6736(14)61060-6.

32. Villar L, Dayan GH, Arredondo-Garcia JL, Rivera DM, Cunha R, Deseda C, et al. Efficacy of a tetravalent dengue vaccine in children in Latin America. N Engl J Med. 2015;372(2):113-23; doi: 10.1056/NEJMoa1411037.

33. Juraska M, Magaret CA, Shao J, Carpp LN, Fiore-Gartland AJ, Benkeser D, et al. Viral genetic diversity and protective efficacy of a tetravalent dengue vaccine in two phase 3 trials. Proceedings of the National Academy of Sciences of the United States of America. 2018;115(36):E8378-E87; doi: 10.1073/pnas.1714250115.

34. Rabaa MA, Girerd-Chambaz Y, Duong Thi Hue K, Vu Tuan T, Wills B, Bonaparte M, et al. Genetic epidemiology of dengue viruses in phase III trials of the CYD tetravalent dengue vaccine and implications for efficacy. Elife. 2017;6; doi: 10.7554/eLife.24196.

35. Waggoner JJ, Balmaseda A, Gresh L, Sahoo MK, Montoya M, Wang C, et al. Homotypic Dengue Virus Reinfections in Nicaraguan Children. The Journal of infectious diseases. 2016;214(7):986-93; doi: 10.1093/infdis/jiw099.

36. Saez-Llorens X, Biswal S, Borja-Tabora C, Fernando L, Liu M, Wallace D, et al. Effect of the Tetravalent Dengue Vaccine TAK-003 on Sequential Episodes of Symptomatic Dengue. The American journal of tropical medicine and hygiene. 2023;108(4):722-6; doi: 10.4269/ajtmh.22-0673.

37. Scaturro P, Cortese M, Chatel-Chaix L, Fischl W, Bartenschlager R. Dengue Virus Non-structural Protein 1 Modulates Infectious Particle Production via Interaction with the Structural Proteins. PLoS pathogens. 2015;11(11):e1005277; doi: 10.1371/journal.ppat.1005277.

38. Hee JR, Cheng D, Chen YH, Wang SH, Chao CH, Huang SW, et al. A non-structural protein 1 substitution of dengue virus enhances viral replication by interfering with the antiviral signaling pathway. Journal of biomedical science. 2025;32(1):25; doi: 10.1186/s12929-024-01116-4.

39. Dos Santos MAM, Pavon JAR, Dias LS, Viniski AE, Souza CLC, de Oliveira EC, et al. Dengue virus serotype 2 genotype III evolution during the 2019 outbreak in Mato Grosso, Midwestern Brazil. Infect Genet Evol. 2023;113:105487; doi: 10.1016/j.meegid.2023.105487.

## Figure legends

**Figure 1: The phylogenetic analysis of DENV2 sequences in Sri Lanka.** The phylogenetic tree was generated with the Sri Lankan DENV2 strains in comparison to a randomized sub-selection of DENV2 serotype 2 strains reported in Asia and South America in the last 30 years (1994-2024). The Sri Lankan DENV2 strains from 2016 onwards (highlighted light blue) cluster together with genotype II, major lineage F strains (dark blue) from East and Southeast Asia, reported in 2013-2018. Genotype II, major lineage A is indicated in red, major lineage C indicated in orange, major lineage D in yellow, genotype 1 in cyan, genotype III in green and genotype V in purple.

**Figure 2: Geographical distribution of Dengue 2 Genotype 2 Lineages**

An illustration of the spatial distribution of the different DENV-2 genotype 2 lineages across the world. Centroids, colour coded according to the major and minor lineages (right-hand-side panel) appear in the geographical locations they have been reported from. Data was accessed from Nextstrain[24].

**Figure 3: Phylogenetic Tree of Dengue Virus Serotype 2 (DENV-2) Derived from Molecular Clock Analysis**. A time-scaled phylogenetic tree was constructed (n=768 sequences) using the Maximum Likelihood method, illustrating the genetic relationships and divergence timing among DENV-2 strains collected from Sri Lanka (n=63) and various global locations (n=705). Each branch is scaled according to the molecular clock, with branch lengths proportional to the estimated amount of evolutionary time elapsed. Clockor2 [28] was

used to perform root-to-tip regression analysis to infer global and local strict molecular clocks Significant nodes are highlighted with asterisks, denoting posterior probabilities greater than 0.95, indicating strong support for these clades. Scale bar indicates nucleotide substitutions per site. Colors (green shades) represent different geographic origins as mentioned in the key above the tree. Global Line (Black Line). In this molecular clock, a generally linear trend is observed, supporting a clock-like evolution.

**Figure 4**. **A heatmap of non-synonymous mutations within the envelope and NS1 regions identified in the DENV-2 genotype II.F.I strains from Sri Lanka.** Rows correspond to individual samples, which are in chronological order from top to bottom (2016 to 2023) and columns correspond to specific E: or NS1: amino acid substitutions. Mutations are in the order of their positions in the E and NS1 region. A light-yellow cell indicates the absence (0) of the indicated mutation, while a light-blue cell indicates its presence (1). The color bar to the right shows the binary scale for presence and absence. The 2022/2023 samples at the bottom show 3 new mutations not seen in the samples sequenced from 2016 to 2018.

**Supplementary Figure 1:** Phylogenetic analysis of DENV2 genotype II strains. The phylogenetic tree was generated with 152 DENV2 genotype II strains (global and Sri Lankan) with the major lineages A, B,C,D,E,F denoted in different colours indicated in the colour key on the left side. The right inset shows the F major lineage with the Sri Lankan sequences (white font) and the global sequences they cluster with.


Tree scale: 0.01
2_I
2_II_A
2_II_C
2_II_D
2_II_F
2_II_F_SL
2_III
2_V

2_II_F Clade

'2017-08/1-10176 |China|MH110579.1'
'2017-08/1-10176 |China|MH110576.1'
'2019/1-10721 |Singapore|MW512497.1'
'2019/1-10721 |Singapore|MW512496.1'
'2018/1-10721 |Singapore|MW512487.1'
'2017/1-10724 |China|MH827554.1'
'2018-09-23/1-10716 |China|MK543448.1'
'2018/1-10723 |Singapore|MW512485.1'
'2019-10/1-10723 |Singapore|MW186240.1'
'2013/1-10723 |Singapore|MW512395.1'
'2014/1-10723 |Singapore|MW512418.1'
'2016/1-10594 |Singapore|MF314189.1'
'2016/1-10723 |Singapore|MW512456.1'
'2016-02-23/1-10707 |Singapore|KU948303.1'
'2016/1-10723 |Singapore|MW512462.1'
'2016/1-10723 |Singapore|MW512461.1'
'2014/1-10723 |Singapore|MW512423.1'
'2015-03/1-10723 |Singapore|KY921905.1'
'2014/1-10723 |Singapore|MW512421.1'
'2015-12-30/1-10724 |China|MN018365.1'
'2018 TG66/1-10723'
'2018 R12/1-10723'
'2018 S36/1-10723'
'2018 Y32/1-10723 DENV2 2018'
'2018 TG4/1-10723'
'2018 R4/1-10723 2018 '
'2018 TG48/1-10723 DENV2 NIID'
'2018 TG11/1-10723'
'2018 TG46/1-10723 2018 DENV2'
'2018 Y37/1-10723'
'2018 TG64/1-10723 2018 DENV2'
'2018 R5/1-10723 2018 DENV2'
'2018 TG33/1-10723'
'2018 TG6/1-10723'
'2018 TG10/1-10723'
'2018 Y25/1-10723'
'2018 R14/1-10723 2018 DENV2'
'2018 M101A/1-10723'
'2018 M111A/1-10723 2018 DENV2'


Dengue 2 Lineages Globally
75
50
25
0
−25
−50
−75
−150
−100
−50
0
50
100
150
2II
2II_A
2II_A.1
2II_A.1.1
2II_A.1.1.1
2II_A.1.1.2
2II_A.1.2
2II_A.2.2
2II_B
2II_C
2II_C.1
2II_C.2
2II_D
2II_D.1
2II_D.1.2
2II_D.2
2II_D.3
2II_E
2II_E.1
2II_E.2
2II_F
2II_F.1
2II_F.1.1
2II_F.1.1.1
2II_F.1.1.2
2II_F.1.1.3
2II_F.1.1.4
2II_F.1.1.5
2II_F.1.2
2II_F.1.3
2II_F.2
2II_F.2.1
2II_F.2.2


Global
2II
2III
2III_A
2III_A.1
2III_A.2
2III_B
2III_C
2III_C.1
2III_C.1.1
2III_C.1.2
2III_C.2
2III_D
2III_D.1
2III_D.1.1
2III_D.1.2
2III_D.1.3
2III_D.2
2III_D.3
2III_E
2II_A
2II_A.1
2II_A.1.1
2II_A.1.1.1
2II_A.1.1.2
2II_A.1.2
2II_A.2.1
2II_A.2.2
2II_B
2II_C
2II_C.1
2II_D
2II_D.1.2
2II_D.2
2II_D.3
2II_E
2II_E.1
2II_E.2
2II_F
2II_F.1
2II_F.1.1
2II_F.1.1.1
2II_F.1.1.2
2II_F.1.1.3
2II_F.1.1.4
2II_F.1.1.5
2II_F.1.1.6
2II_F.1.2
2II_F.1.3
2II_F.2.1
2II_F.2.2
2IV
2V
2VI
2V_A
2V_A.1
2V_A.1.1
2V_A.1.3
2V_A.2
2V_A.3
2V_A.4
2V_B
2V_C
2V_D
2V_E
0.32
0.3
0.28
0.26
0.24
0.22
0.2
1970
1980
1990
2000
2010
2020


Sample name
Y42
Y40
Y39
Y38
Y37
Y36
Y32
Y29
Y25
TG9
TG66
TG65
TG64
TG49
TG48
TG47
TG46
TG45
TG41
TG40
TG39
TG33
TG11
TG10
S36
R91
R9
R86
R78
R74
R64
R5
R48
R4
R34
R25
R24
R19
R14
R12
R10
R1
P55
P15
P119
A2D283/46
A2D157/43
A2D145/42
E:E360G
E:E71A
E:H149N
E:I164V
E:I462V
E:I484V
E:M6I
E:N390S
E:Q52H
E:R120T
E:T171I
E:T176I
E:T478S
E:V129I
E:V309M
E:W453C
NS1:D281E
NS1:F178S
NS1:F279L
NS1:H224L
NS1:I21V
NS1:I264T
NS1:K16R
NS1:K174R
NS1:K272R
NS1:K9N
NS1:I247F
NS1:N10S
NS1:N191D
NS1:N222S
NS1:Q131H
NS1:Q253H
NS1:S128L
NS1:S128P
NS1:S980T
NS1:T117A
NS1:T164M
NS1:T265A
NS1:V177A
NS1:V60A
mutation
0
1